Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine

Bone metastasis is one of the most common causes of skeletal morbidity in patients with advanced cancer and is manifested as osteoblastic and osteolytic lesions. Bone metastasis occurs as an organized and multistep process involving tumor intravasation and the survived tumor cells in circulation. Ex...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 22; no. 11; p. 1546
Main Authors Barghash, Reham F, Abdou, Wafaa M
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.03.2016
Subjects
Animals
Bone Neoplasms - drug therapy
Bone Neoplasms - physiopathology
Bone Neoplasms - secondary
Bone Resorption - prevention & control
Diphosphonates - therapeutic use
Humans
Online AccessGet more information

Cover

More Information
Summary:Bone metastasis is one of the most common causes of skeletal morbidity in patients with advanced cancer and is manifested as osteoblastic and osteolytic lesions. Bone metastasis occurs as an organized and multistep process involving tumor intravasation and the survived tumor cells in circulation. Extravasation into the secondary site, initiation of tumorgenesis and angiogenesis are also included in developing the bone metastasis. Several studies demonstrated that Zoledronic acid, which belongs to the second generation of BP (nitrogen-containing BPs) class agents, is an important and well-established drug in the treatment of wide range of cancer patients, such as breast cancer, prostate cancer, and multiple myeloma associated with bone metastases.
ISSN:1873-4286
DOI:10.2174/1381612822666160122093810